A Novel Synbiotic Alleviates Autoimmune Hepatitis by Modulating the Gut Microbiota-Liver Axis and Inhibiting the Hepatic TLR4/NF-κB/NLRP3 Signaling Pathway
Yongbo Kang, Xiaoyu Kuang, Huan Yan, Peng Ren, Xiaodan Yang, Haixia Liu, Qingqing Liu, Hao Yang, Xing Kang, Xiaorong Shen, Mingwei Tong, Lin Li, Xiaohui Wang, Linzhi Guo, Jieqiong Ma, Fan Zhang, Weiping Fan
Abstract
Synbiotics can ameliorate liver injury and improve liver function by reducing hepatic inflammation and pyroptosis. Our data indicate that our new Syn not only reverses gut dysbiosis by increasing beneficial bacteria and decreasing lipopolysaccharide (LPS)-bearing Gram-negative bacteria but also maintains intestinal barrier integrity. Thus, its mechanism might be associated with modulating gut microbiota composition and intestinal barrier function by inhibiting the TLR4/NF-κB/NLRP3/pyroptosis signaling pathway in the liver. This Syn is as effective as prednisone in treating AIH without side effects. Based on these findings, this novel Syn represents a potential therapeutic agent for AIH in clinical practice.